Sentences with phrase «cancer drug resistance»

Currently I am pursuing my PhD at the Department of Dermatology of the University Hospital Essen in Germany within the MELGEN ETN, where I am investigating cancer drug resistance in melanoma.

Adult drug resistant cancer cells may contribute to this problem, and the authors discuss these and other cancer drug resistance mechanisms in their recent publication in the September issue of the journal Cancers.

«Breakthrough technique combats cancer drug resistance: Researchers «turn off» multi-drug resistance capabilities in cancer cells.»

Not exact matches

Understanding the biological and genetic basis to drug resistance and cancer progression has enabled researchers to identify and develop a targeted drug that may prove to be beneficial in this type of cancer, without causing unmanageable side - effects.

The memorandum of understanding identified four areas in the life sciences where AAAS and the Cuban Academy of Sciences will seek opportunities for sustained cooperation: emerging infectious diseases, brain disorders, cancer, and antimicrobial drug resistance.

The drug - like compounds can be modified and developed into medicines that target a protein in the human body that is responsible for chemotherapy resistance in cancers, said biochemist Pia D. Vogel, lead author on the scientific paper reporting the discovery.

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells» resistance to paclitaxel.

As a result, P - gp causes resistance of the diseased cells to a majority of drugs currently available for the treatment of cancer, as well as drugs used for treatment of infectious diseases like HIV / AIDS.

So far there's no approved drug on the market that reverses cancer chemotherapy resistance caused by P - glycoprotein, or P - gp for short, said Vogel, a biochemistry professor at SMU.

But Whitehead Institute researchers have found a mechanism underlying this resistance — a mechanism that naturally occurs in many diverse cancer types and that may expose vulnerabilities to drugs that spur the natural cell - death process.

«Naturally occurring mechanism of cancer drug - resistance may itself be a treatment target.»

This could be key given that the underlying mechanisms of metastasis and resistance to cancer drugs are nothing if not complex interactions in a biological system.

The ability for cancer cells to develop resistance to chemotherapy drugs — known as multi-drug resistance — remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to «turn off» their resistance capabilities.

The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs.

«For years, researchers have focused on delivering more chemotherapy drugs into cancer cells using nanoparticles, without targeting the root of drug resistance,» He said.

Women with high levels of FGF1 were less likely to respond to platinum - based drugs, but blocking the gene makes their cells lose their resistance (British Journal of Cancer, DOI: 10.1038 / bjc.2012.410).

While researchers have long worked with nanoparticles for drug delivery, the findings put forth by He and his team represent a crucial breakthrough in addressing multidrug resistance in cancer cells.

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibcancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.

This same pathway has been linked to drug resistance in other types of cancer, Guo said.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

Analyzing data from thousands of cancer lines and tumors, the researchers found that those demonstrating resistance to proteasome inhibitor drugs were marked by suppressed expression of one or more of the cells» proteasome cap subunits (which are a subsets of the larger proteasome).

Published in the journal Molecular Cancer Therapeutics, the study also found that use of a second inhibitor might improve the effectiveness of these drugs by possibly preventing resistance, and it recommends that clinical trials should be designed to include a second inhibitor.

Designing molecules that selectively target thiols produced by cancer cells that cause drug resistance is the focus of many years» work by Dimmock, Das and their collaborators.

Das explained that since the compounds they've developed make cancer cells more sensitive to attack, they also remove resistance to standard chemotherapy drugs — a serious problem in current therapies.

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer.

The team found that if they raised glutathione levels in cancer cells in the lab, they reversed resistance to the drug erlotinib, and the treatment was once again able to kill cancer cells.

Although alternative drugs are available once erlotinib stops working, these are much more expensive — and they can also stop working due to cancer cells developing resistance.

«Recent studies suggest that epigenetic modifications may contribute to the development of cancer progenitor cells that can induce drug resistance and the relapse of different types of cancer,» said Sibaji Sarkar, PhD, instructor of medicine at BUSM.

Drug resistance is a major problem in cancer treatment, as drug resistant cancers are thought to be the primary cause of cancer relaDrug resistance is a major problem in cancer treatment, as drug resistant cancers are thought to be the primary cause of cancer reladrug resistant cancers are thought to be the primary cause of cancer relapse.

Such a lag time, says Hahn, could allow cancer cells to develop resistance to a drug by finding some other way to maintain their telomeres.

The drug that they have developed appears to target cancer stem cell activity, which suggests it will prevent metastatic recurrence and be useful in combatting drug resistance.»

«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»

Unfortunately, the drug usually stops working within a few months, due to cancer cells developing resistance to the treatment.

«We've also started exchanging ideas and information with scientists facing related challenges, such as resistance to herbicides in weeds and resistance to drugs in cancer cells,» Tabashnik said.

AAAS and the Cuban Academy of Sciences signed a historic agreement in 2014 to cooperate in four areas: infectious disease, cancer, resistance to antimicrobial drugs, and neurological and neurodegenerative disease.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

The research explains how tumors evolve and cause cancer resistance to drugs designed to match the patient's unique genomic makeup.

While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.

However, the researchers uncovered several mechanisms leading to tumor resistance, giving them insight into which drugs could combat the resistant cancer.

He says it's also important to understand the protein's biological role in cellular signaling and normal animal development as well as to consolidate its role in human cancer development, progression and drug - resistance.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

While the prognosis for kidney cancer that has not spread is good, patients with advanced or metastatic cancer will develop drug resistance.

Some patients respond to the drug for years, but in other patients, the treatment either fails early, or the cancer evolves resistance.

These are aimed specifically at pathways involved in either the initiation and progression of cancer or its resistance to conventional drugs.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

The regrowth of cancer stem cells is responsible for the drug resistance that develops in many breast tumors and the reason that for many patients, the benefits of chemo are short - lived.

Scientists at the Wellcome Trust Sanger Institute and the Institute for Research on Cancer and Ageing of Nice in France, show that high genetic diversity can prime new mutations that cause drug resistance.

In animal and cell culture studies, the drug inhibited growth both in estrogen - dependent breast cancer cells and in cells that had developed resistance to the anti-estrogen tamoxifen and / or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen - dependent breast cancer.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

The researchers write that «depletion of mutant p53 may reduce drug resistance and lead to new strategies for treating cancer in the clinic.»